Trial Profile
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 1: Interleukin-5 Antagonists - Mepolizumab and Reslizumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary) ; Reslizumab (Primary)
- Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Eosinophilic oesophagitis; Hypereosinophilic syndrome; Nasal polyps; Sinusitis
- Focus Pharmacodynamics
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Apr 2021.
- 08 Jan 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Apr 2021.